The life sciences consulting market is growing — that much is not in dispute. What matters more for anyone thinking about their next career move is where within that market the growth is real, sustained, and translating into genuine hiring activity at senior level. The answer in 2026 is more nuanced than it has been in recent years, and the firms adding headcount are doing so for specific reasons tied directly to client demand.
The overall market is on a clear upward trajectory. Valued at around $35 billion globally in 2025, the sector is forecast to reach close to $38 billion in 2026 and to approach $60 billion by 2031 — a compound annual growth rate of around nine percent. That growth is not evenly distributed. It is concentrated in specific service areas, and the firms with the strongest positions in those areas are the ones actively building their teams.
Real-world evidence is the fastest-growing practice area — and the hardest to staff
The single fastest-growing service segment within life sciences consulting right now is real-world evidence. NICE updated its methods guidance in 2024 to formally incorporate RWE into reimbursement decisions, and the European Medicines Agency has reinforced that direction. The result is a sustained increase in demand for consulting teams that can design and deliver RWE programmes to the standard that HTA bodies and payers now expect.
Firms are responding by expanding their RWE practices — but the talent required to do this well is in genuinely short supply. Consultants who combine biostatistics and epidemiology depth with the client-facing, project leadership skills that senior consulting roles demand are rare. The practices growing fastest in this space are those that have invested in developing talent internally over several years rather than trying to buy it in at senior level from a market that cannot supply it.
Market access and HEOR remains the largest segment and is still hiring
Despite RWE's faster growth rate, market access and HEOR consulting retains the largest share of the overall market — around thirty percent. This segment is not standing still. Demand is being sustained by the combination of an increasingly complex payer landscape, rising evidence standards across European markets, and a pharmaceutical industry that is bringing more products to more markets simultaneously than at any point in the last decade.
The firms hiring most actively within market access and HEOR in 2026 are those that have built integrated offerings — combining payer strategy, economic modelling, and value communication into a single service rather than three separate workstreams. Clients are consistently choosing integrated partners over fragmented ones, and firms that have made that integration real — not just in their pitch materials but in how they actually staff and deliver — are growing accordingly.
The firms hiring most confidently in 2026 are not those with the broadest capability — they are those with the deepest position in the two or three areas where client demand is clearest and most sustained.
Launch strategy and commercial consulting is the momentum story of 2026
GLP-1 launch strategy and cell and gene therapy commercialisation are the two highest-growth project types that specialist pharma boutiques are hiring against right now. Both reflect the same underlying dynamic: a pharmaceutical pipeline that is rich in late-stage assets, and a client base that lacks the internal capacity to manage complex multi-market commercial preparation without specialist support.
The firms growing fastest in commercial consulting in 2026 share a specific profile. They have genuine depth in one or two therapeutic areas — not broad coverage, but specific expertise that clients can immediately identify as relevant to their situation. They have senior people who can lead complex, multi-workstream engagements without constant Partner oversight. And they have a track record of completed launches that they can point to directly when competing for new mandates.
Where the jobs actually are: a practice-by-practice view
For consultants actively considering a move, the honest summary of where hiring is concentrated in 2026 looks like this. Market access and HEOR Director and Principal hiring is active across the UK, Europe, and the US, with the strongest demand in London, Zurich, and the major US hubs. RWE is growing fast but the candidate pool is narrow, which means firms are competing hard for a small number of people. Launch strategy and New Product Planning is generating consistent senior mandates — the demand is real, but so is the bar on therapeutic area depth. Digital and AI-adjacent roles within consulting are emerging but remain early-stage at Director level in most firms.
The broader signal is that this is a market rewarding specialism. Consultants with genuine depth in a defined area are in more demand — and have more options — than at any point in the recent past. Those operating as generalists at senior level are finding the market less accommodating than it was even two or three years ago.